Accepted Manuscript



Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

Frédéric Sedel, Delphine Bernard, Donald M. Mock, Ayman Tourbah

PII: S0028-3908(15)30073-3

DOI: 10.1016/j.neuropharm.2015.08.028

Reference: NP 5974

To appear in: *Neuropharmacology*

Received Date: 7 April 2015

Revised Date: 24 July 2015

Accepted Date: 18 August 2015

Please cite this article as: Sedel, F., Bernard, D., Mock, D.M, Tourbah, A., Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis, *Neuropharmacology* (2015), doi: 10.1016/j.neuropharm.2015.08.028.

Title: Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

Authors: Frédéric Sedel[a], Delphine Bernard[a], Donald M Mock[b], Ayman Tourbah[c]

Affiliations:

a. MedDay Pharmaceuticals, ICM-Brain and Spine Institute-IPEPs, Groupe Hospitalier Pitié Salpêtrière, 47 Boulevard de l'Hopital, 75013, Paris, France

b. Departments of Biochemistry & Molecular Biology and Pediatrics, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA

c. Department of Neurology and Faculté de Médecine de Reims, CHU de Reims, URCA, 45 Rue Cognacq Jay, 51092 Reims Cedex, France

Author email addresses:

frederic.sedel@medday-pharma.com; delphine.bernard@medday-pharma.com; MockDonaldM@uams.edu; atourbah@chu-reims.fr

Running title: Mode of action of high-dose biotin in multiple sclerosis

Corresponding author:

Frédéric Sedel

MedDay Pharmaceuticals

ICM-Brain and Spine Institute-IPEPs

Groupe Hospitalier Pitie Salpetriere

47 Boulevard de l'Hopital

75013, Paris, France

Email: frederic.sedel@medday-pharma.com; Tel : 00 33(0)1 57 27 47 58 ; Fax: 00 33(0)1 84 17 76 04